CN104524559A - Lysostaphic complex enzyme oral cavity disinfectant and preparation method thereof - Google Patents
Lysostaphic complex enzyme oral cavity disinfectant and preparation method thereof Download PDFInfo
- Publication number
- CN104524559A CN104524559A CN201410775174.5A CN201410775174A CN104524559A CN 104524559 A CN104524559 A CN 104524559A CN 201410775174 A CN201410775174 A CN 201410775174A CN 104524559 A CN104524559 A CN 104524559A
- Authority
- CN
- China
- Prior art keywords
- parts
- disinfectant
- oral cavity
- ora
- sorbitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a lysostaphic complex enzyme oral cavity disinfectant and a preparation method thereof. The lysostaphic complex enzyme oral cavity disinfectant comprises the following components in parts by mass: 20-40 parts of lysostaphin, 21-41 parts of antibacterial peptide, 21-41 parts of chlorhexidine acetate, 31-42 parts of sorbitol, 21-31 parts of sodium dihydrogen phosphate and 21-30 parts of disodium hydrogen phosphate. The oral cavity disinfectant can be used for treating oral cavity diseases, has the advantages of remarkable curative effect and no alcohol and drug resistance. The invention further discloses a preparation method of the oral cavity disinfectant. The preparation method comprises the following steps: 1) dissolving the lysostaphin, the ntibacterial peptide and the hlorhexidine acetate into distilled water, stirring to completely dissolve the lysostaphin, the ntibacterial peptide and the hlorhexidine acetate; 2) dissolving sorbitol into distilled water, and stirring to completely dissolve the sorbitol; 3) dissolving the sodium dihydrogen phosphate and the disodium hydrogen phosphate into distilled water, and stirring to completely dissolve the sodium dihydrogen phosphate and the disodium hydrogen phosphate; and 4) uniformly mixing solutions obtained in the steps 1), 2) and 3), and then filling the mixed solution. The preparation method has the advantages of simple process and strong operability.
Description
Technical field
The invention belongs to disinfectant field, be specifically related to a kind of composite lysostaphin ora, disinfectant and preparation method thereof.
Background technology
Along with industrial expansion, the problem such as environmental pollution, air quality are defective becomes the chief threat of health of people.Oral cavity is as the important component part of human respiratory, digestive system, and its contact with environment is inevasible, and the incidence rate of thing followed oral disease also substantially increases.
There are numerous pathogenic bacterium in oral cavity, the pathogenic bacterium wherein accounting for major portion have anaerobe, Hemolytic streptococcus, staphylococcus, Candida albicans etc., these pathogenic bacterium are roots of oral disease, they affect the normal absorption of human nutrition material, can cause the generation of the oral diseases such as halitosis, oral ulcer, gingivitis, periodontitis, aphtha simultaneously.Due to the particularity of oral environment, conventional disinfectant can not be applicable to the treatment of oral disease.For the particularity of oral environment, medical circle conducts in-depth research, and has developed the ora, disinfectant that treatment oral disease is special.At present, all containing components such as ethanol, wetting agent, first nitre Cuo in the disinfectant for the treatment of oral disease, although such disinfectant has fungistatic effect to some pathogenic bacterium in oral cavity, but the chemical drugs in component easily makes patient produce drug resistance, has larger stimulation to oral mucosa and intestinal tract simultaneously.
Summary of the invention
For the above-mentioned technical problem that prior art exists, the object of this invention is to provide a kind of composite lysostaphin ora, disinfectant, it may be used for treating oral disease, there is therapeutic effect remarkable, not containing ethanol, drug resistance can not be produced, the advantage little to oral cavity irritation on mucous membrane.
In order to solve the problems of the technologies described above, the present invention adopts following technical scheme:
A kind of composite lysostaphin ora, disinfectant, comprises the component of following mass fraction: staphylococcus lysozyme 20 ~ 40 parts, antibacterial peptide 21 ~ 41 parts, chlorhexidine acetate 21 ~ 41 parts, sorbitol 31 ~ 42 parts, sodium dihydrogen phosphate 21 ~ 31 parts and sodium hydrogen phosphate 21 ~ 30 parts.
In this programme, prepare ora, disinfectant using staphylococcus lysozyme as primary raw material, its sterilizing mechanisms is the cell wall by By Direct Pyrolysis pathogenic bacterium, thus reaches the object of thoroughly sterilization, and patient can be avoided to produce drug resistance; Simultaneously with antibacterial peptide and chlorhexidine acetate with the use of, wherein chlorhexidine acetate has good killing effect to staphylococcus aureus and Candida albicans, antibacterial peptide then has the kill activity of high wide spectrum to gram-bacteria, by three with the use of, the effect of Synergistic can be played, the ora, disinfectant obtained is made to have higher Disinfection Effect, bacterial kill rate.
In this programme, the mass fraction of each component is: staphylococcus lysozyme 20 ~ 40 parts, antibacterial peptide 21 ~ 41 parts, chlorhexidine acetate 21 ~ 41 parts, sorbitol 31 ~ 42 parts, sodium dihydrogen phosphate 21 ~ 31 parts and sodium hydrogen phosphate 21 ~ 30 parts; Such component proportion, in the bacteriolyze process of staphylococcus lysozyme, effect for antibacterial peptide after dissolving staphylococcal bacteria ferment treatment creates condition thus makes antibacterial peptide show obvious enhancement effect, make bacteria lysis dead, make the two play synergistic function, thus final germicidal spray have higher germicidal efficiency.Sorbitol can make staphylococcus lysozyme keep greater activity, thus disinfectant better can play disinfective action; Potassium dihydrogen phosphate and dipotassium hydrogen phosphate can make the germicidal spray obtained have suitable pH value, the ora, disinfectant obtained is made to have the longer holding time, make the active component in disinfectant in suitable acid or alkali environment simultaneously, can carry out disinfection to oral cavity, throat etc. for a long time, effectively ensure that bactericidal effect.
In this programme, the content of staphylococcus lysozyme is 20 ~ 40 parts, this is because the special strain environment in oral cavity is formulated, because in oral cavity except the pathogenic bacterium be harmful to containing some, also have the healthy strain of maintenance as yeast etc., if the consumption of staphylococcus lysozyme is few less than 20 mass parts, the object killing harmful pathogenic bacteria can not be played, otherwise large usage quantity then can to the strain environmental effects in oral cavity more than 40 mass parts, and then the oral mucosa of patient can be stimulated and affect the intestinal health of patient.
As optimization, composite lysostaphin ora, disinfectant comprises the component of following mass fraction: staphylococcus lysozyme 30 parts, antibacterial peptide 30 parts, acetic acid chlorine 30 parts, sorbitol 40 parts, sodium dihydrogen phosphate 21 parts and sodium hydrogen phosphate 30 parts.
In this programme, containing staphylococcus lysozyme 30 parts in composite lysostaphin ora, disinfectant, antibacterial peptide 30 parts, acetic acid chlorine 30 parts, sorbitol 40 parts, sodium dihydrogen phosphate 21 parts and sodium hydrogen phosphate 30 parts, such component proportion is the result of applicant after test of many times checking, such component proportion: on the one hand, sorbitol can ensure that staphylococcus lysozyme fully plays the disinfective action of self, and keeps bactericidal activity for a long time; On the other hand, staphylococcus lysozyme, antibacterial peptide and chlorhexidine acetate are respectively 30 parts, 30 parts and 30 parts, and such content can kill the pathogenic bacterium in oral cavity, simultaneously can not to the strain environmental effects in oral cavity; 3rd, sodium dihydrogen phosphate 21 parts and sodium hydrogen phosphate 30 parts, make the pH value of the composite lysostaphin ora, disinfectant obtained in optimal scope, ensure that the performance of each component usefulness in disinfectant.Such composite lysostaphin oral disinfecting and the pathogenic bacterium that can kill rapidly in oral cavity.
As optimization, the mass ratio of described sodium hydrogen phosphate and sodium dihydrogen phosphate is 7:10.
In this programme, mass ratio is adopted to be that the sodium hydrogen phosphate of 7:10 and sodium dihydrogen phosphate are configured to buffer solution, on the one hand, such buffer solution can the guarantee pH environment of long period can not change, thus ensure that disinfectant can store the longer time and its Disinfection Effect can not be made to reduce; On the other hand, disinfectant and when acting in oral cavity, buffer solution can ensure that the usefulness that can not affect each active component because of the change of oral cavity strain environment plays.
As optimization, the mass ratio of described staphylococcus lysozyme, described antibacterial peptide and described chlorhexidine acetate is 1:1:1.
In this programme, the mass ratio of staphylococcus enzyme, antibacterial peptide and chlorhexidine acetate is 1:1:1, three can be made to be formed perfectly coordinate and produce the effect of Synergistic, make disinfectant can kill pathogenic bacterium in oral cavity fast, stimulation can not be produced to oral mucosa, the more acceptant such Therapeutic Method of suffering from oral disease simultaneously.
Present invention also offers the preparation method of above-mentioned composite lysostaphin ora, disinfectant, specifically comprise the steps:
1) staphylococcus lysozyme, antibacterial peptide and chlorhexidine acetate are dissolved in distilled water, stir and make it dissolve completely;
2) sorbitol is dissolved in distilled water, stirs and make it dissolve completely;
3) sodium dihydrogen phosphate and sodium hydrogen phosphate are dissolved in distilled water, stir and make it dissolve completely;
4) by step 1), 2) and 3) the solution stirring mix homogeneously that obtains, carry out fill.
In this programme, staphylococcus lysozyme, antibacterial peptide and chlorhexidine acetate are dissolved in distilled water, make the abundant mix homogeneously of component with bactericidal effect like this, and in the bacteriolyze process of staphylococcus lysozyme, bactericidal action for antibacterial peptide after dissolving staphylococcal bacteria ferment treatment creates condition, thus making antibacterial peptide show obvious enhancement effect, three is with the use of antibacterial rapid cleavage can be made dead; Sorbitol is dissolved in distilled water the solution system forming stable homogeneous, is conducive to sorbitol and mixs homogeneously with other components; Sodium dihydrogen phosphate and sodium hydrogen phosphate are dissolved in distilled water and form the stable buffer solution of pH value, then mix with other components, the performance of each component in mixed process can not be changed because of the change of pH value, be of value to component property to stablize, ensure that ora, disinfectant has good bactericidal effect.
Compared to existing technology, technical scheme of the present invention has following beneficial effect:
1) take staphylococcus lysozyme as raw material, it is biological enzyme component, and safety and environmental protection can kill antibacterial fast, can not damage Oral Mucosal Cells simultaneously; Simultaneously with antibacterial peptide and chlorhexidine acetate with the use of, adopt dual breaking cellular wall biological antibiotic mechanism, make the ora, disinfectant obtained have higher disinfection efficiency, there is no toxic and side effects simultaneously, patient also can not be made to produce drug resistance.
2) ora, disinfectant pH value of the present invention is gentle, little to the zest of oral mucosa, and patient can not be made to produce uncomfortable sensation; The strain environment in oral cavity can not be affected; The pathogenic bacterium in oral cavity can be killed fast.
3) containing sorbitol component in ora, disinfectant of the present invention, making effective ingredient can have higher activity in the long period, for having good Disinfection Effect during oral disinfecting.
4) ora, disinfectant of the present invention has stable performance, is easy to the advantage that stores, the holding time is long.
5) preparation method of composite lysostaphin ora, disinfectant of the present invention has that technique is simple, the advantage of strong operability.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is described in further detail.
one, specific embodiment:
A kind of composite lysostaphin germicidal spray, comprises the component of following mass fraction: staphylococcus lysozyme 20 ~ 40 parts, antibacterial peptide 21 ~ 41 parts, chlorhexidine acetate 21 ~ 41 parts, sorbitol 31 ~ 42 parts, sodium dihydrogen phosphate 21 ~ 31 parts and sodium hydrogen phosphate 21 ~ 30 parts.Concrete component proportion is as shown in table 1, and the composite lysostaphin ora, disinfectant that wherein prepared by embodiment 1 ~ 4 is designated as respectively: 1#, 2#, 3# and 4#; Ora, disinfectant comparative example prepared is designated as respectively: 5#, 6# and 7#.
The preparation method of above-mentioned composite lysostaphin ora, disinfectant, comprises following preparation process:
1) staphylococcus lysozyme, antibacterial peptide and chlorhexidine acetate are dissolved in distilled water, stir and make it dissolve completely;
2) sorbitol is dissolved in distilled water, stirs and make it dissolve completely;
3) sodium dihydrogen phosphate and sodium hydrogen phosphate are dissolved in distilled water, stir and make it dissolve completely;
4) by step 1), 2) and 3) the solution stirring mix homogeneously that obtains, carry out fill.
Table 1
| Component | 1# | 2# | 3# | 4# | 5# | 6# | 7# |
| Staphylococcus lysozyme/mass parts | 30 | 20 | 39 | 25 | 30 | 0 | 30 |
| Antibacterial peptide/mass parts | 30 | 41 | 20 | 26 | 0 | 30 | 0 |
| Chlorhexidine acetate/mass parts | 30 | 41 | 23 | 22 | 0 | 30 | 30 |
| Sorbitol/mass parts | 40 | 30 | 35 | 36 | 40 | 40 | 40 |
| Sodium dihydrogen phosphate/mass parts | 21 | 21 | 30 | 21 | 21 | 21 | 21 |
| Sodium hydrogen phosphate/mass parts | 30 | 21 | 22 | 30 | 30 | 30 | 30 |
Two,
performance Detection
1, the bactericidal effect test of oral cavity, throat:
Choose arbitrarily the patient that 35 have oral problem, wherein the range of age is 18 ~ 60 years old, and the sign of patient checks as shown in table 2; For the oral problem of patient, give the 1# composite lysostaphin ora, disinfectant that every patient's dispenser every day embodiment 1 obtains respectively, concrete application method is: dispenser every day 4 times, every minor tick 3 hours, again examination of mouth is carried out after using one week, check result is as shown in table 2, wherein in check result: effectively for symptom after dispenser disappears completely; Part effectively alleviates or partial remission for symptom after dispenser, wherein effective percentage=efficiently individual quantity/problem number; Invalid for using rear symptom still to exist, without any alleviating or disappearing; Wherein part effective percentage=part efficiently individual quantity/problem number.
Table 2
| Oral problem | Problem number of cases | Efficiently individual quantity | Effective percentage | Part efficiently individual quantity | Part effective percentage | Invalid number |
| Oral ulcer | 30 | 28 | 93.3% | 2 | 6.7% | 0 |
| Halitosis | 29 | 26 | 89.7% | 3 | 10.3% | 0 |
| Gingivitis | 28 | 22 | 78.6% | 6 | 21.4% | 0 |
| Periodontitis | 33 | 24 | 72.7% | 9 | 27.3% | 0 |
| Aphtha | 31 | 29 | 93.5% | 2 | 6.5% | 0 |
| Pharyngolaryngitis | 35 | 22 | 62.6% | 10 | 37.4% | 0 |
By above result of the test surface, composite lysostaphin ora, disinfectant prepared by the present invention has good biological antibiotic effect, fast to the healing speed of oral problem, there is the advantage of colorless and odorless, wherein for oral diseases such as oral ulcer, halitosis, gingivitis, periodontitis, aphtha, pharyngolaryngitis, there is significant therapeutic effect and mitigation.
2, oral disease contrast test:
Choose arbitrarily the patient having oral problem, wherein the range of age is 20 ~ 60 years old, every routine disease gets 7 patients, then administration 1# ~ 7# is distinguished, wherein every patient application method of often planting case is identical, be: dispenser every day 3 times, each dispenser is spaced apart 8 hours, dispenser checked after one week, check result is as shown in table 3, cure in table and represent that symptom is eliminated completely after dispenser, after improving situation represents dispenser, symptom alleviates or part is eliminated, and after not obvious expression dispenser, symptom alleviates not obvious or symptom and do not alleviate.
Table 3
| Oral disease | 1# | 2# | 3# | 4# | 5# | 6# | 7# |
| Oral ulcer | Cure | Cure | Cure | Cure | Improving situation | Not obvious | Improving situation |
| Halitosis | Cure | Cure | Cure | Cure | Improving situation | Improving situation | Improving situation |
| Gingivitis | Cure | Cure | Improving situation | Improving situation | Not obvious | Not obvious | Not obvious |
| Periodontitis | Cure | Improving situation | Improving situation | Improving situation | Not obvious | Not obvious | Not obvious |
| Aphtha | Cure | Cure | Cure | Cure | Improving situation | Improving situation | Not obvious |
| Pharyngolaryngitis | Improving situation | Improving situation | Improving situation | Improving situation | Not obvious | Not obvious | Not obvious |
As can be seen from Table 3,1# ~ 4# composite lysostaphin ora, disinfectant has significant therapeutic effect to oral disease, and after patient administration, symptom has improvement or cures, and it has eradicative rate fast and efficiently to the pathogenic bacterium in oral cavity; Comparative example 5#, 6# and 7# only have effect to part oral problem, and effect is not remarkable, therefrom can find out: remarkable to the therapeutic effect of oral disease when the proportioning of staphylococcus lysozyme, antibacterial peptide and chlorhexidine acetate is 1:1:1, this is because for the special strain environment in oral cavity, such component proportion can make three play the effect of Synergistic, and lacking of any one component all can not reach significant therapeutic effect.
The above embodiment of the present invention is only for example of the present invention is described, and is not the restriction to embodiments of the present invention.For those of ordinary skill in the field, other multi-form change and variations can also be made on the basis of the above description.Here cannot give exhaustive to all embodiments.Every belong to technical scheme of the present invention the apparent change of amplifying out or variation be still in the row of protection scope of the present invention.
Claims (5)
1. a composite lysostaphin ora, disinfectant, is characterized in that, comprises the component of following mass fraction: staphylococcus lysozyme 20 ~ 40 parts, antibacterial peptide 21 ~ 41 parts, chlorhexidine acetate 21 ~ 41 parts, sorbitol 31 ~ 42 parts, sodium dihydrogen phosphate 21 ~ 31 parts and sodium hydrogen phosphate 21 ~ 30 parts.
2. composite lysostaphin ora, disinfectant according to claim 1, is characterized in that, comprises the component of following mass fraction: staphylococcus lysozyme 30 parts, antibacterial peptide 30 parts, acetic acid chlorine 30 parts, sorbitol 40 parts, sodium hydrogen phosphate 21 parts and sodium dihydrogen phosphate 30 parts.
3. composite lysostaphin ora, disinfectant according to claim 1, is characterized in that, the mass ratio of described sodium hydrogen phosphate and sodium dihydrogen phosphate is 7:10.
4. composite lysostaphin ora, disinfectant according to claim 1, is characterized in that, the mass ratio of described staphylococcus lysozyme, described antibacterial peptide and described chlorhexidine acetate is 1:1:1.
5. a preparation method for the composite lysostaphin compound enzyme ora, disinfectant as described in any one of claim 1 ~ 4, is characterized in that, comprise following preparation process:
1) staphylococcus lysozyme, antibacterial peptide and chlorhexidine acetate are dissolved in distilled water, stir and make it dissolve completely;
2) sorbitol is dissolved in distilled water, stirs and make it dissolve completely;
3) sodium dihydrogen phosphate and sodium hydrogen phosphate are dissolved in distilled water, stir and make it dissolve completely;
4) by step 1), 2) and 3) the solution stirring mix homogeneously that obtains, carry out fill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410775174.5A CN104524559A (en) | 2014-12-16 | 2014-12-16 | Lysostaphic complex enzyme oral cavity disinfectant and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410775174.5A CN104524559A (en) | 2014-12-16 | 2014-12-16 | Lysostaphic complex enzyme oral cavity disinfectant and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104524559A true CN104524559A (en) | 2015-04-22 |
Family
ID=52840313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410775174.5A Pending CN104524559A (en) | 2014-12-16 | 2014-12-16 | Lysostaphic complex enzyme oral cavity disinfectant and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104524559A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104996467A (en) * | 2015-08-12 | 2015-10-28 | 江苏绿科生物技术有限公司 | Complex lysostaphin disinfectant |
| CN105169378A (en) * | 2015-08-12 | 2015-12-23 | 江苏绿科生物技术有限公司 | Preparation method of complex lysostaphin disinfectant |
| CN106938046A (en) * | 2017-03-16 | 2017-07-11 | 韦毅 | A kind of antibacterial peptide complex enzyme oral spray |
| CN107280997A (en) * | 2017-06-20 | 2017-10-24 | 江苏开源康达医疗器械有限公司 | A kind of composite lysozyme sterilization ora, disinfectant and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327854A (en) * | 2000-06-08 | 2001-12-26 | 上海高科生物工程有限公司 | Composite lysostaphin enzyme spray for oral cavity and its preparing process |
| CN1488400A (en) * | 2003-08-18 | 2004-04-14 | 上海高科生物工程有限公司 | Preparation for preventing and curing endometritis for dairy cattle and preparing method thereof |
-
2014
- 2014-12-16 CN CN201410775174.5A patent/CN104524559A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327854A (en) * | 2000-06-08 | 2001-12-26 | 上海高科生物工程有限公司 | Composite lysostaphin enzyme spray for oral cavity and its preparing process |
| CN1488400A (en) * | 2003-08-18 | 2004-04-14 | 上海高科生物工程有限公司 | Preparation for preventing and curing endometritis for dairy cattle and preparing method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李阳友: "生物消毒剂及其前景", 《兽药与牧草》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104996467A (en) * | 2015-08-12 | 2015-10-28 | 江苏绿科生物技术有限公司 | Complex lysostaphin disinfectant |
| CN105169378A (en) * | 2015-08-12 | 2015-12-23 | 江苏绿科生物技术有限公司 | Preparation method of complex lysostaphin disinfectant |
| CN106938046A (en) * | 2017-03-16 | 2017-07-11 | 韦毅 | A kind of antibacterial peptide complex enzyme oral spray |
| CN107280997A (en) * | 2017-06-20 | 2017-10-24 | 江苏开源康达医疗器械有限公司 | A kind of composite lysozyme sterilization ora, disinfectant and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1740166B1 (en) | Therapeutic antimicrobial compositions and methods | |
| CN103285028B (en) | Composite antibacterial agent of chitosan and organosilicone quaternary ammonium salt and preparation method of composite antibacterial agent | |
| EP2330081A2 (en) | Oxidative reductive potential water solution, processes for producing same and methods of using the same | |
| CN106309237A (en) | Hyaluronic acid private part care gel and preparation method thereof | |
| CN101189017A (en) | Method of using oxidative reductive potential water solution in dental applications | |
| MXPA05009960A (en) | Oxidative reductive potential water solution, processes for producing same and methods of using the same. | |
| CN104524559A (en) | Lysostaphic complex enzyme oral cavity disinfectant and preparation method thereof | |
| CN102028705A (en) | Gynecologic article containing biological antifungal components | |
| CN111449973A (en) | Foaming agent for restoring microecological balance of female vagina and preparation method thereof | |
| CN105168238A (en) | Hyaluronic temperature-sensitive gel and preparation method and application thereof | |
| WO2008104076A1 (en) | Electrocolloidal silver and echinacea root antimicrobial formulation | |
| CN102100723A (en) | Special disinfectant for pet | |
| CN103379918A (en) | Oral composition and method of forming and using same | |
| CN104606672A (en) | Staphylococcus-dissolving composite enzyme sterilization spraying agent and preparation method thereof | |
| CN109223760B (en) | Application of benzofuran derivative | |
| CN106267329A (en) | A kind of plants essential oil gel dressing and its preparation method and application | |
| CN104147603A (en) | Application of novel marine algae extractive composition in preventing virus flu | |
| CN111214409A (en) | No-clean disinfectant and preparation method thereof | |
| CN101972271A (en) | Chlorine dioxide mucous membrane gel and preparation method thereof | |
| CN111632073A (en) | Antibacterial and anti-inflammatory female privates probiotic composition and preparation thereof | |
| CN101310702B (en) | Emulsion type gel preparation containing chlorhexidine and alcohol | |
| CN110623919A (en) | Hydrogen-ion-rich acidic maintenance contraceptive gel for gynecology and preparation method thereof | |
| CN104906131B (en) | A kind of preparation method preventing and treating lamb stomatitis plaster | |
| CN107753930A (en) | The preparation and its application of nisin, Cetylpyridinium Chloride and sodium fluoride mouthwash | |
| CN107970257A (en) | A kind of ear pharmaceutical composition, preparation method and applications and ear pharmaceutical preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150422 |
|
| RJ01 | Rejection of invention patent application after publication |